Navigation Links
High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
Date:12/10/2013

BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the high cost per patient per year of biologics and novel oral therapies for the treatment of rheumatoid arthritis (RA) and psoriasis often results in reimbursement hurdles that limit patients' ability to access these therapies. Among RA patients in the United States who are eligible but do not receive a biologic/novel oral therapy (approximately 10 percent of disease-modifying antirheumatic [DMARD]-treated RA patients), more than 35 percent do not receive treatment because of cost-related issues, and approximately 20 percent do not receive treatment because of payer restrictions.

The new Strategic Insights report entitled Trends in Reimbursement for Immune Biologics: Strategies for Success also finds that in an attempt to control the increasing costs associated with biologics/novel oral agents, particularly the non-TNF-alpha inhibitors, payers frequently use a wide range of strategies and tactics such as prior authorization, step-therapy requirements and blocking copay assistance programs for nonpreferred agents.

"As new biologics/novel oral agents and biosimilars enter the RA and psoriasis markets, drug marketers can expect more payer scrutiny and restrictions," said Decision Resources Analyst Adi Reske, Ph.D. "Payers will demand extensive data and greater discounts and rebates to justify giving a therapy preferred coverage. To overcome the increasing barriers, drug marketers must employ different strategies including more cost-effective agents, head-to-head clinical data, and greater discounts and rebates."

About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) ... Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... symptomatic relief of cough in adults and children 6 years ... ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... , Feb. 17, 2017  In partnership with ... for Good Health , The Jack Brewer Foundation ... with millions of dollars, worth of medicine to ... . IHI is a non-profit dedicated to treating chronic ... extremely active in Haiti and ...
(Date:2/17/2017)... NEW YORK , February 17, 2017 ... Composite and the S&P 500 edged lower at the ... its bullish streak above the 20,000 benchmark. Moreover, five ... bearish territories. Taking into consideration yesterday,s market sentiment, Stock-Callers.com ... morning: Smith & Nephew PLC (NYSE: SNN ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... , ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea ...
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Diego, CA (PRWEB) , ... February 17, 2017 ... ... initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively impact ... , “The Board of Trustees has long considered it our duty to seriously ...
Breaking Medicine News(10 mins):